Comparison · NCT02015637-sae
Delafloxacin vs Ceftriaxone: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Delafloxacin vs Ceftriaxone: serious adverse events. Trial comparisons, record NCT02015637-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02015637-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0125 | wilson | |
| Risk in group 2 | 0.00649 | 0.00115 | 0.0359 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00649 | -0.0359 | 0.00708 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Delafloxacin than on Ceftriaxone | 154 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Delafloxacin | 900mg orally (2 x 450 mg tablets) administered once~Delafloxacin: single dose | 0 | 304 | EG000 |
| Group 2 | Ceftriaxone | Ceftriaxone 250 mg intramuscular injection administered once~Ceftriaxone: single dose | 1 | 154 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All Adverse Events (AEs) occurring from the time the subject signed the Informed Consent Form (ICF) through the follow-up phone contact were reported and followed to resolution. Collection of all AEs occurred from the time the subject received study drug (Day 1) through the TOC visit (Day 7 +/- 3), or up to 10 days. Only Serious Adverse Events (SAEs) were collected after the TOC visit through the follow-up phone contact (Day 30 +/- 3 days), or up to 33 days.
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea
- NCT number
- NCT02015637
- Phases
- PHASE3
- Conditions
- Gonorrhea
- Interventions
- Delafloxacin, Ceftriaxone
- Lead sponsor
- Melinta Therapeutics, Inc.
- Results first posted
- 2018-04-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02015637?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02015637-sae